Search results for: NICE

Revisiting rarity: Would yesterday’s NICE highly...

Objectives:  ​​In March 2025, NICE adopted new HST routing criteria for evaluating technolo...

Read more
Navigating NICE’s HST Pathway: Insights from Bot...

NICE’s Highly Specialised Technologies (HST) Programme offers a vital route for bringing ultra-rar...

Read more
NICE Summary Guide 2025: What the Appraisal Reform...

NICE has introduced important appraisal reforms for 2025 that will directly impact manufacturers pre...

Read more
NICE Submission Checklist: Your Guide to STA &...

Preparing a NICE submission can feel overwhelming. Whether it’s a Single Technology Appraisal (STA...

Read more
From submission to guidance: Demystifying the NICE...

The vast majority of products launching in the UK will be assessed by the National Institute for Hea...

Read more
NICE 2025 Update: How New Appraisal Reforms Impact...

The National Institute of Health and Care Excellence (NICE) has published several updates and releas...

Read more
Avoiding pitfalls: Top 5 reasons NICE HST/STA subm...

Most pharmaceutical products hoping to launch in the UK will be assessed by NICE as a Single Technol...

Read more
Mastering NICE submissions: The three pillars for ...

Securing a positive recommendation from the National Institute for Health and Care Excellence (NICE)...

Read more
HST or STA? Navigating NICE’s Dual Pathways for ...

When bringing a new health technology to market in England, pharmaceutical and biotech companies mus...

Read more
25 Years of NICE: Reflections and Achievements

Celebrating its 25th anniversary, NICE hosted a conference looking back at its progress and ahead to...

Read more
Older

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch